Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Accel. buyback
Quarterly results
Auditor change
AbbVie Inc. (ABBV) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/04/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
07/27/2023 8-K Quarterly results
Docs: "AbbVie Reports Second-Quarter 2023 Financial Results"
07/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/27/2023 8-K Quarterly results
04/05/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
03/28/2023 8-K Quarterly results
02/09/2023 8-K Quarterly results
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "J.P. Morgan Healthcare Conference | January 10, 2023 2 Forward - Looking Statements and Non - GAAP Financial Information Some statements in this presentation are, or may be considered, forward - looking statements for purposes of the Private Securitie s Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or cond iti onal verbs, generally identify forward - looking statements. AbbVie cautions that these forward - looking statements are subject to risks and un certainties that may cause actual results to differ materially from those expressed or implied in the forward - looking statements. Such risks and uncertainties include, but are not limited to, challenges..."
01/06/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
11/29/2022 8-K Quarterly results
10/28/2022 8-K Quarterly results
10/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "ABBVIE VICE CHAIRMAN OF EXTERNAL AFFAIRS AND CHIEF LEGAL OFFICER LAURA SCHUMACHER TO RETIRE Perry Siatis Named as Executive Vice President, General Counsel and Secretary"
10/14/2022 8-K Appointed a new director
Docs: "SECOND AMENDED AND RESTATED BY-LAWS OF",
"AGREEMENT REGARDING"
10/05/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense"
07/29/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
06/29/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/29/2022 8-K Quarterly results
04/21/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "AbbVie Inc. Reconciliation of Reported GAAP and Non-GAAP Results to Revised Non-GAAP Results Quarter Ended March 31, 2021 Earnings Diluted Pre-tax After-tax b EPS As reported $ 3,867 $ 3,553 $ 1.99 Specified items, as originally reported 2,141 1,715 0.96 As adjusted , as originally reported 6,008 5,268 2.95 Previously specified items a As adjusted , revised $ 5,898 $ 5,159 $ 2.89 Quarter Ended June 30, 2021 Earnings Diluted Pre-tax After-tax b EPS As reported $ 1,163 $ 766 $ 0.42 Specified items, as originally reported 5,195 4,790 2.69 As adjusted , as originally reported 6,358 5,556 3.11 Previously specified items a As adjusted , revised $ 6,226 $ 5,424 $ 3.03 Quarter Ended September 30, 2021 Earnings Diluted Pre-tax After-tax b EPS As reported $ 3,688 $ 3,179 $ 1.78 Specified items, a..."
04/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/04/2022 8-K Quarterly results
02/02/2022 8-K Quarterly results
Docs: "AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results"
12/17/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/16/2021 8-K Quarterly results
10/29/2021 8-K Quarterly results
Docs: "AbbVie Reports Third-Quarter 2021 Financial Results"
08/19/2021 8-K Other Events  Interactive Data
07/30/2021 8-K Quarterly results
Docs: "AbbVie Reports Second-Quarter 2021 Financial Results"
05/10/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy